 SOUTH PLAINFIELD, N.J., April 15, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy SMA treated with EvrysdiTM risdiplam obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk. 